(b)(4) initial emdr submission.A follow up emdr will be submitted if additional information becomes available.(b)(4).No additional information was provided by (b)(6).(b)4) did reach out to obtain with no success.Should additional information be available in the future, the complaint will be re-opened and investigated.All complaints are reviewed during monthly quality/safety meetings.In addition, complaints are trended at monthly quality data analyst meetings and quarterly plant management review meetings.
|
Material no.: unknown batch no.: unknown.It was reported that the patient experienced skin irritation while using chloraprep.Describe reaction(s)(include relevant test/lab data) ( cont.) chloraprep dressing kits (form of admin, route of admin, and batch number were not reported) dose, frequency, and therapy dates were not reported for an unspecified indication concomitant medications included pirfenidone, tadalafil, and treprostinil sodium on an unspecified date, the patient experienced skin irritation.The action taken with macitentan was not reported; and the action taken with chloraprep dressing kits was not reported.The outcome of skin irritation was not reported.The reporter provided no causality assessment company causality between macitentan, and skin irritation was not related.This report was non-senous.This case, involving the same patient is linked to (b)(4).
|